HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $46
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $32 to $46.
Login to comment